1. Home
  2. EOD vs BCYC Comparison

EOD vs BCYC Comparison

Compare EOD & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Global Dividend Opportunity Fund of Beneficial Interest

EOD

Allspring Global Dividend Opportunity Fund of Beneficial Interest

HOLD

Current Price

$6.22

Market Cap

272.6M

Sector

Finance

ML Signal

HOLD

Logo Bicycle Therapeutics plc

BCYC

Bicycle Therapeutics plc

HOLD

Current Price

$3.64

Market Cap

291.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EOD
BCYC
Founded
2007
2009
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
272.6M
291.8M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
EOD
BCYC
Price
$6.22
$3.64
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $9.50
AVG Volume (30 Days)
112.5K
★ 472.1K
Earning Date
01-01-0001
11-06-2026
Dividend Yield
★ 9.28%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.51
$3.33
52 Week High
$6.74
$9.08

Technical Indicators

Market Signals
Indicator
EOD
BCYC
Relative Strength Index (RSI) 39.71 47.63
Support Level $5.92 $3.37
Resistance Level $6.53 $3.99
Average True Range (ATR) 0.08 0.18
MACD -0.01 0.00
Stochastic Oscillator 24.34 42.16

Price Performance

Historical Comparison
EOD
BCYC

About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest

Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.

Share on Social Networks: